Capital Increase in Genmab as a Result of Employee Warrant Exercise

Written by Customer Service on . Posted in Public Companies.

Company AnnouncementCopenhagen, Denmark; November 12, 2019 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 56,329 shares as a consequence of the exercise of employee warrants.The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:900 shares at DKK 31.75,
1,100 shares at DKK 40.41,
45,000 shares at DKK 80.55,
500 shares at DKK 98.00,
250 shares at DKK 210.00,
525 shares at DKK 220.40,
1,600 shares at DKK 225.90,
135 shares at DKK 231.50,
397 shares at DKK 337.40,
275 shares at DKK 466.20,
800 shares at DKK 623.50,
1,500 shares at DKK 636.50,
88 shares at DKK 815.50,
1,150 shares at DKK 939.50,
2,029 shares at DKK 1,145.00 and
80 shares at DKK 1,424.00.Proceeds to the company are approximately DKK 9.61 million. The increase corresponds to approx. 0.087% of the company’s share capital.The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2019. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.Pursuant to section 32 of the Danish Capital Markets Act No 459 of April 24, 2019, it is hereby announced, that the total nominal value of Genmab A/S’ share capital after the capital increase is DKK 65,074,502 which is made up of 65,074,502 shares of a nominal value of DKK 1 each, corresponding to 65,074,502 votes.About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab’s technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with core sites in Utrecht, the Netherlands and Princeton, New Jersey, U.S.For Investor Relations:
Andrew Carlsen, Senior Director, Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Company Announcement no. 54
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment20191112_CA54_Warrant Exercise

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.